Griesbacher Thomas, Rainer Irmgard, Tiran Beate, Evans D Michael
Institute for Experimental and Clinical Pharmacology, University of Graz, Universitätsplatz 4, A-8010 Graz, Austria.
Br J Pharmacol. 2002 Nov;137(5):692-700. doi: 10.1038/sj.bjp.0704910.
In order to investigate the mechanism of kinin release leading to vascular symptoms in acute interstitial-oedematous pancreatitis, the novel, selective inhibitors of tissue kallikrein, (2S,2'R)-2-(2'-amino-3'-(4'-chlorophenyl)propanoylamino)-N-(3-guanidinopropyl)-3-(1-naphthyl)propanoamide (FE999024, CH-2856), and of plasma kallikrein, (2'S,2"R)-4-(2'-(2"(carboxymethylamino)-3"-cyclohexyl-propanoylamino)-3'-phenyl-propanoylamino)piperidine-1-carboxamidin (FE999026, CH-4215), were used in experimental caerulein-induced pancreatitis in rats. Oedema formation and plasma protein extravasation during the 2 h infusion of caerulein were inhibited in a dose-dependent manner by i.p. pretreatment with FE999024 (7-60 micromol kg(-1)) while FE999026 had no effect at the same doses. Haemoconcentration and hypovolaemia associated with the pancreatic oedema formation during pancreatitis were significantly attenuated by FE999024 at a dose of 20 micro mol kg(-1). The reduction in circulating plasma volume was not affected by FE999026. Accumulation of amylase and lipase in the pancreas was dose-dependently reduced by FE999024 while enzyme activities in the blood serum were increased by FE999024 at 60 micromol kg(-1) indicating improved enzyme removal from the tissue. Enzyme activities in the tissue and in the blood remained unaffected by FE999026. FE999024 (20 micromol kg(-1)) largely inhibited increased tissue kallikrein-like activity in the pancreas during acute pancreatitis and also strongly attenuated influx of plasma kallikrein into the tissue. FE999026 (20 micromol kg(-1)) significantly inhibited plasma kallikrein-like activity in the pancreas but had no effect on tissue kallikrein-like activity. In conclusion, vascular kinin-mediated symptoms observed during oedematous pancreatitis in the rat are caused by the action of tissue kallikrein in the pancreas whereas an involvement of plasma kallikrein seems to be unlikely.
为了研究急性间质性水肿性胰腺炎中导致血管症状的激肽释放机制,在大鼠实验性蛙皮素诱导的胰腺炎中使用了新型的组织激肽释放酶选择性抑制剂(2S,2'R)-2-(2'-氨基-3'-(4'-氯苯基)丙酰氨基)-N-(3-胍基丙基)-3-(1-萘基)丙酰胺(FE999024,CH-2856)和血浆激肽释放酶选择性抑制剂(2'S,2"R)-4-(2'-(2"(羧甲基氨基)-3"-环己基-丙酰氨基)-3'-苯基-丙酰氨基)哌啶-1-甲脒(FE999026,CH-4215)。腹腔注射FE999024(7-60微摩尔/千克)预处理可剂量依赖性地抑制蛙皮素输注2小时期间的水肿形成和血浆蛋白外渗,而相同剂量的FE999026则无作用。胰腺炎期间与胰腺水肿形成相关的血液浓缩和血容量不足在FE999024剂量为20微摩尔/千克时得到显著减轻。循环血浆量的减少不受FE999026的影响。FE999024剂量依赖性地减少胰腺中淀粉酶和脂肪酶的积聚,而血清中酶活性在FE999024剂量为60微摩尔/千克时增加,表明从组织中清除酶的能力得到改善。组织和血液中的酶活性不受FE999026的影响。FE999024(20微摩尔/千克)在很大程度上抑制了急性胰腺炎期间胰腺中组织激肽释放酶样活性的增加,并且也强烈减弱了血浆激肽释放酶向组织中的流入。FE999026(20微摩尔/千克)显著抑制胰腺中的血浆激肽释放酶样活性,但对组织激肽释放酶样活性无作用。总之,大鼠水肿性胰腺炎期间观察到的血管激肽介导的症状是由胰腺中组织激肽释放酶的作用引起的,而血浆激肽释放酶似乎不太可能参与其中。